Towards cannabis and cannabinoid treatment of multiple sclerosis

Drugs of Today

Volumn 40, Issue 8, 2004, Pages 663-676

  Croxford, J Ludovic ^a,b   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BETA INTERFERON; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; DANTROLENE; DIAZEPAM; DRONABINOL; GABAPENTIN; GLATIRAMER; MYELIN; NABILONE;

ANALGESIA; ANXIETY DISORDER; BLADDER DYSFUNCTION; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HALLUCINATION; HUMAN; HYPOTENSION; IMMUNOMODULATION; META ANALYSIS; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; REVIEW; SEIZURE; SELF MEDICATION; SIDE EFFECT; SPASTICITY; TREMOR; XEROSTOMIA;

ANIMALS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS, PHASE III; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; JAPAN; MULTICENTER STUDIES; MULTIPLE SCLEROSIS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CANNABINOID;

EID: 4644273102     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.8.850469     Document Type: Review

References (101)

1. Vincent, B.J., McQuiston, D.J., Einhorn, L.H., Nagy, C.M., Brames, M.J. Review of cannabinoids and their antiemetic effectiveness. Drugs 1983, 25(Suppl. 1): 52-62.
2. Croxford, J.L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003, 17: 179-202.
3. Devane, W.A., Dysarz, F.A., Johnson, M.R., Melvin, L.S., Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharm 1988, 34: 605-13.
4. Matsuda, L.A., Lolait, S.J., Brownstein, M.J., Young, A.C., Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346: 561-4.
5. Munro, S., Thomas, K.L., Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365: 61-5.
6. Howlett, A.C., Qualy, J.M., Khachatrian, L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharm 1986, 29: 307-13.
7. Pacheco, M.A., Ward, S.J., Childers, S.R. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Res 1993, 603: 102-10.
8. Yamaguchi, F., Macrae, A.D., Brenner, S. Molecular cloning of two cannabinoid type 1-like receptor genes from the puffer fish Fugu rubripes. Genomics 1996, 35: 603-5.
9. De Petrocellis, L., Melck, D., Bisogno, T., Milone, A., Di Marzo, V. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: Possible role in the feeding response. Neuroscience 1999, 92: 377-87.
10. Stefano, G.B., Salzet, B., Salzet, M. Identification and characterization of the leech CNS cannabinoid receptor: Coupling to nitric oxide release. Brain Res 1997, 753: 219-24.
11. Chang, M.C., Berkery, D., Schuel, R. et al. Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Rep Devel 1993, 36: 507-16.
12. Bisogno, T., Ventriglia, M., Milone, A., Mosca, M., Cimino, G., Di Marzo, V. Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim Biophys Acta 1997, 1345:338-48.
13. Herkenham, M., Lynn, A.B., Johnson, M.R., Melvin, L.S., de Costa, B.R., Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991, 11: 563-83.
14. Glass, M., Dragunow, M., Faull, R.L. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77: 299-318.
15. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Therap 1997, 74: 129-80.
16. Howlett, A.C., Mukhopadhyay, S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000, 108: 53-70.
17. Mu, J., Zhuang, S.Y., Kirby, M.T., Hampson, R.E., Deadwyler, S.A. Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Therap 1999, 291: 893-902.
18. Ishac, E.J., Jiang, L., Lake, K.D., Varga, K., Abood, M.E., Kunos, G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br J Pharmacol 1996, 118: 2023-8.
19. Kathmann, M., Bauer, U., Schlicker, E., Gothert, M. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn-Schmiedebergs Archiv Pharmacol 1999, 359: 466-70.
20. Nakazi, M., Bauer, U., Nickel, T., Kathmann, M., Schlicker, E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedebergs Archiv Pharmacol 2000, 361: 19-24.
21. Wilson, R.I., Nicoll, R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410: 588-92.
22. Shen, M., Piser, T.M., Seybold, V.S., Thayer, S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996, 16: 4322-34.
23. Galiegue, S., Mary, S., Marchand, J. et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232: 54-61.
24. Lynn, A.B., Herkenham, M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Therap 1994, 268: 1612-23.
25. Klein, T.W., Newton, C., Friedman, H. Cannabinoid receptors and immunity. Immunol Today 1998, 19: 373-81.
26. Klein, T.W., Lane, B., Newton, C.A., Friedman, H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000, 225: 1-8.
27. Klein, T.W., Newton, C., Zhu, W., Daaka, Y., Friedman, H. Delta 9-tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc Soc Exp Biol Med 1995, 209: 205-12.
28. Lu, Q., Straiker, A., Lu, Q., Maguire, G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 2000, 17: 91-5.
29. Griffin, G., Fernando, S.R., Ross, R.A. et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol 1997, 339: 53-61.
30. Skaper, S.D., Buriani, A., Dal Toso, R. et al. The aliamide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996, 93: 3984-9.
31. Devane, W.A., Hanus, L., Breuer, A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258: 1946-9.
32. Showalter, V.M., Compton, D.R., Martin, B.R., Abood, M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Therap 1996, 278: 989-99.
33. Schmid, P.C., Krebsbach, R.J., Perry, S.R., Dettmer, T.M., Maasson, J.L., Schmid, H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Letters 1995, 375: 117-20.
34. Sugiura, T., Kondo, S., Sukagawa, A. et al. N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. J Lipid Med Cell Signal 1996, 14: 51-6.
35. Felder, C.C., Nielsen, A., Briley, E.M. et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters 1996, 393: 231-5.
36. Baker, D., Pryce, G., Croxford, J.L. et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB Journal 2001, 15: 300-2.
37. Yang, H.Y., Karoum, F., Felder, C., Badger, H., Wang, T.C., Markey, S.P. GC/MS analysis of anandamide and quantification of N- arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J Neurochem 1999, 72: 1959-68.
38. Deutsch, D.G., Goligorsky, M.S., Schmid, P.C. et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997, 100: 1538-46.
39. Schmid, P.C., Paria, B.C., Krebsbach, R.J., Schmid, H.H., Dey, S.K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 1997, 94: 4188-92.
40. Giuffrida, A., Piomelli, D. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. FEBS Letters 1998, 422: 373-6.
41. Mechoulam, R., Ben-Shabat, S., Hanus, L. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50: 83-90.
42. Stella, N., Schweitzer, P., Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388: 773-8.
43. Porter, A.C., Sauer, J.M., Knierman, M.D. et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Therap 2002, 301: 1020-4.
44. Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., Di Marzo, V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Letters 2002, 513: 294-8.
45. Walker, J.M., Krey, J.F., Chu, C.J., Huang, S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002, 121: 159-72.
46. Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., Gilula, N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384: 83-7.
47. Deutsch, D.G., Glaser, S.T., Howell, J.M. et al. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol Chem 2001, 276: 6967-73.
48. Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., Piomelli, D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277: 1094-7.
49. Egertova, M., Giang, D.K., Cravatt, B.F., Elphick, M.R. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Royal Soc London 1998, 265: 2081-5.
50. Maccarrone, M., Valensise, H., Bari, M., Lazzarin, N., Romanini, C., Finazzi-Agro, A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000, 355: 1326-9.
51. Di Marzo, V., Bisogno, T., De Petrocellis, L. et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999, 264: 258-67.
52. Gaoni, Y., Mechoulam, R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971, 93: 217-24.
53. Howlett, A.C., Barth, F., Bonner, T.I. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54: 161-202.
54. Goodin, D.S., Frohman, E.M., Garmany, G.P., Jr. et al., Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002, 58: 169-78.
55. Dubois, B.D., Keenan, E., Porter, B.E. et al. Interferon beta in multiple sclerosis: Experience in a British specialist multiple sclerosis centre. J Neurol Neurosurg Psych 2003, 74: 946-9.
56. Noth, J. Trends in the pathophysiology and pharmacotherapy of spasticity. J Neurol 1991, 238: 131-9.
57. Cutter, N.C., Scott, D.D., Johnson, J.C., Whiteneck, G. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehab 2000, 81: 164-9.
58. Goodkin, D.E. Current disease-modifying therapies in multiple sclerosis. In: Raine, C.S., McFarlin, H.F., Tourtellotte, W.W. (Eds.). Multiple Sclerosis: Clinical and pathogenetic basis. Chapman and Hall, London 1997, 309-23.
59. Pertwee, R.G. Cannabinoids and multiple sclerosis. Pharmacol Therap 2002, 95: 165-74.
60. Consroe, P., Musty, R., Rein, J., Tillery, W., Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997, 38: 44-8.
61. Baker, D., O'Neill, J.K., Gschmeissner, S.E., Wilcox, C.E., Butter, C., Turk, J.L. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 1990, 28: 261-70.
62. Baker, D., Pryce, G., Croxford, J.L. et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404: 84-7.
63. Black, J.A., Dib-Hajj, S., Baker, D., Newcombe, J., Cuzner, M.L., Waxman, S.G. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc Nat Acad Sci USA 2000, 97: 11598-602.
64. Walker, J.M., Huang, S.M., Strangman, N.M., Tsou, K., Sanudo-Pena, M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Nat Acad Sci USA 1999, 96: 12198-203.
65. Farquhar-Smith, W.P., Egertova, M., Bradbury, E.J., McMahon, S.B., Rice, A.S., Elphick, M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 2000, 15: 510-21.
66. Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394: 277-81.
67. Campbell, F.A., Tramer, M.R., Carroll, D., Reynolds, D.J., Moore, R.A., McQuay, H.J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001, 323: 13-6.
68. Sliwa, J.A., Bell, H.K., Mason, K.D., Gore, R.M., Nanninga, J., Cohen, B. Upper urinary tract abnormalities in multiple sclerosis patients with urinary symptoms. Arch Phys Med Rehab 1996, 77: 247-51.
69. Martyn, C.N., Illis, L.S., Thorn, J. Nabilone in the treatment of multiple sclerosis. Lancet 1995, 345: 579.
70. Pertwee, R.G., Fernando, S.R. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharm 1996, 118: 2053-8.
71. Martin, R.S., Luong, L.A., Welsh, N.J., Eglen, R.M., Martin, G.R., MacLennan, S.J. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharm 2000, 129: 1707-15.
72. Jaggar, S.I., Sellaturay, S., Rice, A.S. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci Lett 1998, 253: 123-6.
73. Jaggar, S.I., Hasnie, F.S., Sellaturay, S., Rice, A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998, 76: 189-99.
74. Dmitrieva, N., Berkley, K.J. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci 2002, 22: 7147-53.
75. Matsuda, L.A., Bonner, T.I., Lolait, S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993, 327: 535-50.
76. Athwal, B.S., Berkley, K.J., Hussain, I. et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain 2001, 124 (Pt. 2): 369-77.
77. Palazzo, E., Marabese, I., de Novellis, V. et al. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 2001, 40: 319-26.
78. Fowler, C.J. Brain activation during micturition. Brain 1998, 121 (Pt. 11): 2031-2.
79. Killestein, J., Hoogervorst, E.L., Reif, M. et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002, 58: 1404-7.
80. Zajicek, J., Fox, P., Sander, H. et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 2003, 362: 1517-26.
81. Brady, C.M., DasGupta, R., Wiseman, O.J., Dalton, C.M., Berkley, K.J., Fowler, C.J. The effect of cannabis based medicinal extract on lower urinary tract dysfunction in advanced multiple sclerosis: Preliminary results. J Neurol Neurosurg Psych 2002, 72: 139.
82. GW Pharmaceuticals. Phase III Clinical Trials (accessed 16th December 2003). http://www.gwpharm.com/corp_glan_phas_3.html
83. Lee, S.F., Newton, C., Widen, R., Friedman, H., Klein, T.W. Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. Eur J Pharm 2001, 423: 235-41.
84. Schatz, A.R., Lee, M., Condie, R.B., Pulaski, J.T., Kaminski, N.E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Tox App Pharmacol 1997, 142: 278-87.
85. Pestonjamasp, V.K., Burstein, S.H. Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta 1998, 1394: 249-60.
86. Bisogno, T., Maurelli, S., Melck, D., De Petrocellis, L., Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 1997, 272: 3315-23.
87. Brosnan, C.F., Selmaj, K., Raine, C.S. Hypothesis: A role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol 1988, 18: 87-94.
88. Selmaj, K., Raine, C.S., Cross, A.M. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991, 30: 694-700.
89. Croxford, J.L., Triantaphyllopoulos, K.A., Neve, R.M., Feldmann, M., Chernajovsky, Y., Baker, D. Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor. J Immunol 2000, 64: 2776-81.
90. Croxford, J.L., Triantaphyllopoulos, K., Podhajcer, O.L., Feldmann, M., Baker, D., Chernajovsky, Y. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J Immunol 1998, 160: 5181-7.
91. Croxford, J.L., Miller, S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55.212. J Clin Invest 2003, 111: 1231-40.
92. Arevalo-Martin, A., Vela, J.M., Molina-Holgado, E., Borrell, J., Guaza, C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003, 23: 2511-6.
93. Lyman, W.D., Sonett, J.R., Brosnan, C.F., Elkin, R., Bornstein, M.B. Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989, 23: 73-81.
94. Wirguin, I., Mechoulam, R., Breuer, A., Schezen, E., Weidenfeld, J., Brenner, T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacol 1994, 28: 209-14.
95. Achiron, A., Miron, S., Lavie, V., Margalit, R., Biegon, A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: Implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 2000, 102: 26-31.
96. Coles, A.J., Wing, M.G., Molyneux, P. et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999, 46: 296-304.
97. Wiendl, H., Hohlfeld, R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. Biodrugs 2002, 16: 183-200.
98. Pryce, G., Ahmed, Z., Hankey, D.J. et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003, 126: 2191-202.
99. Werner, P., Pitt, D., Raine, C.S. Glutamate excitotoxicity-a mechanism for axonal damage and oligodendrocyte death in multiple sclerosis? J Neural Transm Suppl 2000, 60: 375-85.
100. Pitt, D., Werner, P., Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000, 6: 67-70.
101. McPartland, J.M., Pruitt, P.L. Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. Altern Therap Health Med 1999, 5: 57-62.